Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer

Tadahiko Shien, Sadako Akashi-Tanaka, Kunihisa Miyakawa, Takashi Hojo, Chikako Shimizu, Kunihiko Seki, Masashi Ando, Tsutomu Kohno, Naruto Taira, Hiroyoshi Doihara, Noriyuki Katsumata, Yasuhiro Fujiwara, Takayuki Kinoshita

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalWorld Journal of Surgery
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Breast Neoplasms
Drug Therapy
Neoplasms
Anthracyclines
Odds Ratio
Tomography
Multivariate Analysis
Neoadjuvant Therapy
Breast
Therapeutics
taxane

ASJC Scopus subject areas

  • Surgery

Cite this

Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. / Shien, Tadahiko; Akashi-Tanaka, Sadako; Miyakawa, Kunihisa; Hojo, Takashi; Shimizu, Chikako; Seki, Kunihiko; Ando, Masashi; Kohno, Tsutomu; Taira, Naruto; Doihara, Hiroyoshi; Katsumata, Noriyuki; Fujiwara, Yasuhiro; Kinoshita, Takayuki.

In: World Journal of Surgery, Vol. 33, No. 1, 01.2009, p. 44-51.

Research output: Contribution to journalArticle

Shien, T, Akashi-Tanaka, S, Miyakawa, K, Hojo, T, Shimizu, C, Seki, K, Ando, M, Kohno, T, Taira, N, Doihara, H, Katsumata, N, Fujiwara, Y & Kinoshita, T 2009, 'Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer', World Journal of Surgery, vol. 33, no. 1, pp. 44-51. https://doi.org/10.1007/s00268-008-9800-9
Shien, Tadahiko ; Akashi-Tanaka, Sadako ; Miyakawa, Kunihisa ; Hojo, Takashi ; Shimizu, Chikako ; Seki, Kunihiko ; Ando, Masashi ; Kohno, Tsutomu ; Taira, Naruto ; Doihara, Hiroyoshi ; Katsumata, Noriyuki ; Fujiwara, Yasuhiro ; Kinoshita, Takayuki. / Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. In: World Journal of Surgery. 2009 ; Vol. 33, No. 1. pp. 44-51.
@article{d5f92dbb31c0448db2cb11d03c924396,
title = "Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer",
abstract = "Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. The overall response and pCR rates in these patients were 86{\%} and 17{\%}, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.",
author = "Tadahiko Shien and Sadako Akashi-Tanaka and Kunihisa Miyakawa and Takashi Hojo and Chikako Shimizu and Kunihiko Seki and Masashi Ando and Tsutomu Kohno and Naruto Taira and Hiroyoshi Doihara and Noriyuki Katsumata and Yasuhiro Fujiwara and Takayuki Kinoshita",
year = "2009",
month = "1",
doi = "10.1007/s00268-008-9800-9",
language = "English",
volume = "33",
pages = "44--51",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer

AU - Shien, Tadahiko

AU - Akashi-Tanaka, Sadako

AU - Miyakawa, Kunihisa

AU - Hojo, Takashi

AU - Shimizu, Chikako

AU - Seki, Kunihiko

AU - Ando, Masashi

AU - Kohno, Tsutomu

AU - Taira, Naruto

AU - Doihara, Hiroyoshi

AU - Katsumata, Noriyuki

AU - Fujiwara, Yasuhiro

AU - Kinoshita, Takayuki

PY - 2009/1

Y1 - 2009/1

N2 - Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.

AB - Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.

UR - http://www.scopus.com/inward/record.url?scp=58149293601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149293601&partnerID=8YFLogxK

U2 - 10.1007/s00268-008-9800-9

DO - 10.1007/s00268-008-9800-9

M3 - Article

C2 - 18953600

AN - SCOPUS:58149293601

VL - 33

SP - 44

EP - 51

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 1

ER -